November 12, 2017, Sunday
Omni Active Health is planning to invest 150 cr in over 3-4 years. Omni Active Health Technologies, a leading nutraceutical company is looking at strategic acquisitions in domestic and foreign markets.
NOV 10, 2017,Friday
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY)
First disclosure of anti-tumor activity from the bladder and cervical cancer cohorts showed objective response rates of 32% and 14%, respectively, and was 46% and 25% in patients who express PD-L1 ≥1% Increased proliferating cytotoxic T cell count and decreased kynurenine production were also observed, providing evidence of immunomodulation within the tumor Safety profile is consistent with that previously reported for the BMS-986205 plus Opdivo combination.
Paris, France - October 12, 2017
Expansion at Val de Reuil reinforces the company’s position as a global leader in seasonal flu vaccines
Geneva, 12 November 2017
Over 109 million children in the developing world have now received pneumococcal conjugate vaccine (PCV)
Sign up to hear from our team.